Still a lot more basic, translational, and clinical trials and many years until we proved that approaches such as this can provide a work. ‘.

About the UAB Division of Clinical Immunology and RheumatologyThe UAB Division of Clinical Immunology and Rheumatology is internationally recognized and the search focuses on new knowledge and translating research findings into more effective diagnosis and treatment of patients with rheumatic diseases.Exploratory clinical study of the FDA and the FDA , and LCP expects registered mail around 300 stable renal transplant patients to the program. The trial will be carried out of approximately 50 locations the U.S. And Europe, and awaits the conclusions of clinical trials with second half of 2010.

To further support the security database and possibly best in class pharmacokinetics on LCP-Tacro made LCPs agreed upon with FDA PK studies at de novo kidney and liver transplant patients. The results from these ongoing studies are expected in the first half of 2009, is expected.. When demonstrated favorable Stage 2 pharmacokinetic dates in stable transplant recipients earlier this year, LCPs was successful meetings with the U.S. Food and Drug Administration day with regard to the further development of LCP-Tacro tablets again. The FDA confirm company strategy the present a? 505 2 applications of LCP-Tacro, making exploitation of existing data from literature, it is expected application for prevention of graft rejection in kidney and liver transplants patient.